To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer.
作者信息
Lipkowitz Stanley, Kohn Elise C
机构信息
National Cancer Institute, National Institutes of Health, Bethesda, MD.
National Cancer Institute, National Institutes of Health, Bethesda, MD
出版信息
J Clin Oncol. 2015 Dec 10;33(35):4127-8. doi: 10.1200/JCO.2015.63.6670. Epub 2015 Oct 5.
Abstract
摘要
相似文献
1
To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer.治疗还是不治疗：激素替代疗法在卵巢癌患者中的应用
J Clin Oncol. 2015 Dec 10;33(35):4127-8. doi: 10.1200/JCO.2015.63.6670. Epub 2015 Oct 5.
2
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.辅助激素治疗可能改善上皮性卵巢癌的生存：AHT 随机试验结果。
J Clin Oncol. 2015 Dec 10;33(35):4138-44. doi: 10.1200/JCO.2015.60.9719. Epub 2015 Sep 28.
3
Hormone therapy for epithelial ovarian cancer.上皮性卵巢癌的激素治疗
Curr Opin Oncol. 2008 Sep;20(5):548-53. doi: 10.1097/CCO.0b013e3283063912.
4
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.用于治疗复发性上皮性卵巢癌的促黄体生成素释放激素（LHRH）激动剂。
Cochrane Database Syst Rev. 2016 Jun 29;2016(6):CD011322. doi: 10.1002/14651858.CD011322.pub2.
5
[Rationale for the approach to the choice of hormone therapy for ovarian cancer].[卵巢癌激素治疗选择方法的理论依据]
Vopr Onkol. 2014;60(3):274-9.
6
Gonadotropin signalling in epithelial ovarian cancer.促性腺激素信号在卵巢上皮性癌中的作用。
Cancer Lett. 2012 Nov 28;324(2):152-9. doi: 10.1016/j.canlet.2012.05.017. Epub 2012 May 22.
7
Hormone response in ovarian cancer: time to reconsider as a clinical target?卵巢癌中的激素反应：是否应重新考虑将其作为临床靶点？
Endocr Relat Cancer. 2012 Nov 9;19(6):R255-79. doi: 10.1530/ERC-12-0175. Print 2012 Dec.
8
Endocrine therapy in epithelial ovarian cancer.上皮性卵巢癌的内分泌治疗
Expert Rev Anticancer Ther. 2017 Feb;17(2):109-117. doi: 10.1080/14737140.2017.1272414. Epub 2016 Dec 24.
9
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.一项随机、开放标签、2 期研究评估 IDO1 抑制剂依匹卡昔单抗（INCB024360）联合他莫昔芬对比他莫昔芬单药治疗仅表现为生物化学复发（CA-125 复发）的上皮性卵巢癌、原发性腹膜癌或输卵管癌。
Gynecol Oncol. 2017 Sep;146(3):484-490. doi: 10.1016/j.ygyno.2017.07.005. Epub 2017 Jul 8.
10
Endocrine therapy in ovarian cancer: where do we stand?卵巢癌的内分泌治疗：我们目前的进展如何？
Curr Opin Obstet Gynecol. 2018 Feb;30(1):17-22. doi: 10.1097/GCO.0000000000000423.
引用本文的文献
1
Hormone replacement therapy after surgery for epithelial ovarian cancer.上皮性卵巢癌手术后的激素替代疗法。
Cochrane Database Syst Rev. 2020 Jan 28;1(1):CD012559. doi: 10.1002/14651858.CD012559.pub2.
本文引用的文献
1
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.辅助激素治疗可能改善上皮性卵巢癌的生存：AHT 随机试验结果。
J Clin Oncol. 2015 Dec 10;33(35):4138-44. doi: 10.1200/JCO.2015.60.9719. Epub 2015 Sep 28.
2
Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative.《妇女健康倡议研究中绝经激素治疗对乳腺癌结局的影响》
J Natl Compr Canc Netw. 2015 Jul;13(7):917-24. doi: 10.6004/jnccn.2015.0106.
3
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.激素受体表达与卵巢癌生存：卵巢肿瘤组织分析联盟研究。
Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.
4
New insights on the role of hormonal therapy in ovarian cancer.激素疗法在卵巢癌中作用的新见解。
Steroids. 2013 Jun;78(6):530-7. doi: 10.1016/j.steroids.2013.01.008. Epub 2013 Feb 8.
5
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.雌激素受体阳性乳腺癌诊断后继续辅助他莫昔芬治疗 10 年与 5 年后停药的长期疗效：ATLAS，一项随机试验。
Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1.
6
Hormone replacement therapy and prognosis in ovarian cancer patients.激素替代疗法与卵巢癌患者预后的关系。
Eur J Cancer Prev. 2013 Jan;22(1):52-8. doi: 10.1097/CEJ.0b013e328355ec22.
7
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.绝经后子宫切除妇女停用结合型马雌激素后的健康结局：一项随机对照试验。
JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382.
8
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.雌激素加孕激素与绝经后妇女的乳腺癌发病率和死亡率。
JAMA. 2010 Oct 20;304(15):1684-92. doi: 10.1001/jama.2010.1500.
9
Breast cancer after use of estrogen plus progestin in postmenopausal women.绝经后妇女使用雌激素加孕激素后发生的乳腺癌。
N Engl J Med. 2009 Feb 5;360(6):573-87. doi: 10.1056/NEJMoa0807684.
10
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.皇家马斯登医院他莫昔芬预防乳腺癌随机双盲试验的20年随访
J Natl Cancer Inst. 2007 Feb 21;99(4):283-90. doi: 10.1093/jnci/djk050.
Zotero 插件